No Data
No Data
Shenlian Biotech (688098.SH): Net loss of 2.09 million yuan in the first quarter
Gelonghui, April 26 | Shenlian Biotech (688098.SH) released its first quarter report. Operating revenue was 880.58 million yuan, up 7.58% year on year, with a net loss of 2.209 million yuan, after deducting non-net loss of 2.889 million yuan, and basic earnings per share of -0.01 yuan.
Express News | Shenlian Biotech: Bovine Tuberous Dermatosis Inactivated Vaccine Obtains Veterinary Drug Product Approval Number Approval
Shenlian Biotech (688098.SH): 2023 net profit of 31,518,700 yuan decreased by 48.42% year-on-year
Gelonghui, Feb. 28, 丨 Shenlian Biotech (688098.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 301.4871 million yuan, down 8.25% from the previous year; net profit attributable to owners of the parent company was 31.518,700 yuan, down 48.42% from the previous year.
Express News | Today, 76 A-share stocks were traded in bulk. Bohai Leasing, China Eastern Airlines, and Kweichow Moutai ranked in the top three in terms of turnover
[BT Financial Report Instantaneous Analysis] Shenlian Biotech's 2023 Quarterly Report: Performance and Market-based Sales Process in the Face of Challenges
Shenlian Biomedical (Shanghai) Co., Ltd. (stock code: 688098) is a high-tech enterprise focusing on R&D, production and sales of veterinary biological products. The company's main business is veterinary preventive biological products and veterinary diagnostic products, and has two major veterinary drug GMP production bases in Shanghai and Lanzhou. The products already marketed by Shenlian Biotech include pig foot-and-mouth disease vaccine, cattle and sheep foot-and-mouth disease vaccine, swine ring vaccine, foot-and-mouth disease and African swine fever diagnostic reagents. Among them, pig foot-and-mouth disease type O and type A bivalent inactivated vaccines are important products of the company. In terms of assets and liabilities, Shenlian Biotech's 2023 three-quarter report shows that the public
Shanghai Hongchao, a shareholder of Shenlian Biotech (688098.SH), and his co-actors reduced their holdings of the company by a total of 2.35%
Shenlian Biotech (688098.SH) announced that Shanghai Hongchao Industrial Investment Co., Ltd. (“Shanghai Hongchao”), a shareholder of the company...
No Data